A COMPARISON OF THE ANTIMUSCARINIC PROPERTIES OF APROPHEN WITH ---ETC(U)

S E FREEMAN, B M PADDLE

MRL-R-794
A COMPARISON OF THE ANTIMUSCARINIC PROPERTIES OF APROPHEN WITH THOSE OF SOME OTHER ANTICHOLINERGIC DRUGS

R.M. Dawson, S.E. Freeman and B.M. Paddle
A COMPARISON OF THE ANTIMUSCARINIC PROPERTIES OF APROPHEN WITH THOSE OF SOME OTHER ANTICHOLINERGIC DRUGS

R. M. Dawson, S. E. Freeman, and B. M. Paddle

ABSTRACT

Apparent dissociation constants (K_i) for the interaction of benactyzine, aprophen and atropine with the muscarinic cholinoreceptor were determined in the brain (striatum and pons-medulla) and ileum of the guinea pig by competition with (3H)-quinuclidinyl benzilate (QNB) in a direct binding assay. Corresponding dissociation constants in the atrium were determined by antagonism of acetylcholine-induced contractions. In all regions studied, aprophen and benactyzine (which are closely related structurally) were approximately equi-effective, based on their K_i values, and about \( \frac{1}{4} \) as effective as atropine. Hyoscine and the glycollate T3436 were also studied in the atrium and found to be more potent muscarinic antagonists than atropine. Values of K_i were in the nanomolar range. For any one antagonist, significant differences were observed between K_i values for different regions.

Concentrations of aprophen in the millimolar range were necessary for it to have any effect on the kinetics of acetylcholinesterase. The effects of aprophen on the enzyme were similar to those previously reported for benactyzine (Dawson and Bladen 1979).

The results extend and complement those of Green et al. (1980) who showed that aprophen was as effective as atropine in the treatment of nerve agent poisoning.

Approved for Public Release

© COMMONWEALTH OF AUSTRALIA 1980

POSTAL ADDRESS: Chief Superintendent, Materials Research Laboratories P.O. Box 50, Ascot Vale, Victoria 3032, Australia
A COMPARISON OF THE ANTIMUSCARINIC PROPERTIES OF APROPHEN WITH THOSE OF SOME OTHER ANTICHOLINERGIC DRUGS

Apparent dissociation constants ($K_i$) for the interaction of benactyzine, aprophen and atropine with the muscarinic cholinocceptor were determined in the brain (striatum and pons-medulla) and ileum of the guinea pig by competition with ($^3$H)-quinuclidinyl benzilate (QNB) in a direct binding assay. Corresponding dissociation constants in the atrium were determined by antagonism of acetylcholine-induced contractions. In all regions studied, aprophen and benactyzine (which are closely related structurally) were approximately equi-effective, based on their $K_i$ values, and about $1/2$ as effective as atropine. Hyoscine and the glycolate T3436 were also studied in the atrium and found to be more potent muscarinic antagonists than atropine. Values of $K_i$ were in the nanomolar range. For any one antagonist, significant differences were observed between $K_i$ values for different regions.
Concentrations of aprophen in the millimolar range were necessary for it to have any effect on the kinetics of acetylcholinesterase. The effects of aprophen on the enzyme were similar to those previously reported for benactyzine (Dawson and Bladen 1979).

The results extend and complement those of Green et. al. (1980) who showed that aprophen was as effective as atropine in the treatment of nerve agent poisoning.
CONTENTS

1. INTRODUCTION 1

2. EXPERIMENTAL PROCEDURES 2
   2.1 Cardiac Muscarinic Receptors 2
   2.2 Direct Binding Studies 2
   2.3 Enzyme Studies 2

3. RESULTS AND DISCUSSION 2
   3.1 Muscarinic Cholinceptors 2
   3.2 Interactions of Aprophen with AChE 3

4. ACKNOWLEDGEMENTS 3

5. REFERENCES 4
   TABLE 1 5
   TABLE 2 6
A COMPARISON OF THE ANTIMUSCARINIC PROPERTIES
OF APROPHEN WITH THOSE OF SOME OTHER
ANTICHOLINERGIC DRUGS

1. INTRODUCTION

There has been interest over a period of years in the possibility of finding an anticholinergic drug which might prove superior to atropine in the treatment of nerve agent poisoning. One could search for a more potent anticholinergic, one with an increased duration of action in the body, or one with better access to the central nervous system. Recent work with benactyzine and the related drug aprophen (in which the OH group of benactyzine has been replaced by CH₃) suggests further that less specific antimuscarinic drugs may be more effective antidotes than atropine (Green et al., 1980). Whether this efficacy derives from blockade of receptors other than the muscarinic cholinoreceptor is uncertain, but the subject is of sufficient importance to warrant further pharmacological study.

Green et al. (1980) evaluated the antimuscarinic properties of atropine and aprophen in the peripheral and central nervous systems by antagonism of carbachol-induced contractions of the guinea pig ileum, and antagonism of oxotremorine-induced tremors in mice, respectively. In the present work we have determined apparent dissociation constants for a number of antimuscarinic drugs (including aprophen) in the guinea pig atrium by the method of Arunlakshana and Schild (1959). In addition, dissociation constants for atropine, aprophen and benactyzine in guinea pig brain and ileum were determined by direct binding studies using the radiolabelled antagonist (H)-quinuclidinyl-benzilate (QNB). Interactions between aprophen and the enzyme acetylcholinesterase (AChE; EC 3.1.1.7) were also studied.

The results indicate that aprophen and benactyzine are of comparable potency, and both are weaker antagonists of the muscarinic receptor than atropine. It was also noted that the muscarinic receptor shows some degree of regional heterogeneity; anticholinergic drugs bind more tightly in the central nervous system than in the periphery.
2. EXPERIMENTAL PROCEDURES

2.1 Cardiac Muscarinic Receptors

The apparent dissociation constant of a number of antagonist drugs was determined for the muscarinic receptor of the guinea pig atrium. Experiments were carried out at 37°C, and acetylcholine chloride was used as the agonist. Log-log plots of dose ratio minus one (DR-1) versus antagonist concentration were constructed (Arumukkata and Schid., 1959) and the apparent dissociation constant, K_i, determined from the intercept at (DR-1) = 1 by means of a least squares regression.

2.2 Direct Binding Studies

Homogenates of guinea pig brain and ileum were prepared and assayed for muscarinic receptors with (3H)-QNB as described by Dawson and Jarrott (1980). Inhibition of QNB binding (44-74 pM) by atropine, benactyzine or aprophen was analysed by means of a Hill plot (equation 1) where Y is the ratio of QNB bound in the presence of inhibitor of concentration I to that in its absence and n_H is the Hill coefficient (Fields et al., 1978).

\[ \log \left[ \frac{Y}{(I-Y)} \right] = n_H \log I \]  

(1)

Apparent values of K_i, the dissociation constant of the inhibitor-receptor complex, were calculated using equation 2 where I_50 is the value of I corresponding to Y = 0.5, K_D is the apparent dissociation constant of the QNB-receptor complex and Q is the concentration of QNB. Values of K_D were taken from Dawson and Jarrott (unpublished results).

\[ K_i = \frac{I_{50}}{(1 + Q/K_D)} \]  

(2)

2.3 Enzyme Studies

Bovine erythrocyte AChE (Sigma) was used. Hydrolysis of the substrate acetylthiocholine, decarbamylation of dimethylcarbamyl-AChE (both in 45 mM phosphate at 25°C), dephosphorylation of diethylphosphoryl-AChE (in 2.5 mM phosphate - 150 mM NaCl at 37°C) and ageing of isopropylmethylphosphonyl-AChE (in 2 mM phosphate - 10 mM NaCl at 37°C) were studied as described by Dawson and Bladen (1979).

3. RESULTS AND DISCUSSION

3.1 Muscarinic Cholinoreceptors

Atropine, benactyzine and aprophen all inhibited binding of the antagonist (3H)-QNB to muscarinic receptors of brain and ileum of the guinea pig with a Hill coefficient, n_H, which was statistically indistinguishable from 1.0 in all cases (Table 1). This indicates a lack of cooperativity in binding and is
2. EXPERIMENTAL PROCEDURES

2.1 Cardiac Muscarinic Receptors

The apparent dissociation constant of a number of antagonist drugs was determined for the muscarinic receptor of the guinea pig atrium. Experiments were carried out at 37°C, and acetylcholine chloride was used as the agonist. Log-log plots of dose ratio minus one (DR-1) versus antagonist concentration were constructed (Arumlaokshana and Schild, 1959) and the apparent dissociation constant, Kᵢ, determined from the intercept at (DR-1) = 1 by means of a least squares regression.

2.2 Direct Binding Studies

Homogenates of guinea pig brain and ileum were prepared and assayed for muscarinic receptors with (3H)-QNB as described by Dawson and Jarrott (1980). Inhibition of QNB binding (44-74 pM) by atropine, benactyzine or aprophen was analysed by means of a Hill plot (equation 1) where Y is the ratio of QNB bound in the presence of inhibitor of concentration I to that in its absence and nₗ is the Hill coefficient (Fields et al., 1978).

\[
\log \left[ \frac{Y}{(1-Y)} \right] = nₗ \log I
\]  

(1)

Apparent values of Kᵢ, the dissociation constant of the inhibitor-receptor complex, were calculated using equation 2 where I₅₀ is the value of I corresponding to Y = 0.5, Kᵢ is the apparent dissociation constant of the QNB-receptor complex and Q is the concentration of QNB. Values of Kᵢ were taken from Dawson and Jarrott (unpublished results).

\[
Kᵢ = \frac{I₅₀}{(1 + Q/Kᵢ)}
\]  

(2)

2.3 Enzyme Studies

Bovine erythrocyte AChE (Sigma) was used. Hydrolysis of the substrate acetylthiocholine, decarbamylation of dimethylcarbamyl-AChE (both in 45 mM phosphate at 25°C), dephosphorylation of diethylphosphoryl-AChE (in 2.5 mM phosphate - 150 mM NaCl at 37°C) and ageing of isopropylmethylphosphonyl-AChE (in 2 mM phosphate - 10 mM NaCl at 37°C) were studied as described by Dawson and Bladen (1979).

3. RESULTS AND DISCUSSION

3.1 Muscarinic Cholinoceptors

Atropine, benactyzine and aprophen all inhibited binding of the antagonist (3H)-QNB to muscarinic receptors of brain and ileum of the guinea pig with a Hill coefficient, nₗ, which was statistically indistinguishable from 1.0 in all cases (Table 1). This indicates a lack of cooperativity in binding and is
characteristic of muscarinic antagonists (Hulme et al., 1978). The three drugs were all potent inhibitors of QNB binding, with $K_i$ values in the range 0.6-9 nM (Table 1). Table 1 also lists apparent values of $K_a$ for a number of muscarinic antagonists acting on the guinea pig atrium. In the two brain regions studied (striatum and pons-medulla) and in the ileum, atropine had the lowest $K_i$ value and benactyzine the highest, although there was little difference between benactyzine and aprophen. These results are consistent with those of Green et al. (1980) who measured antimuscarinic potency by other methods (see Introduction). In the atrium the R-enantiomer of the glycollate T3436 was the most potent antagonist and aprophen was the least potent. The value for $K_i$ for atropine in the atrium is identical with that found in the ileum. The $K_i$ values for aprophen and benactyzine are also similar in atrium and ileum, but the order of potency is reversed. Aprophen is slightly less potent than benactyzine in the atrium, and slightly more potent in the ileum. The differences may be more a function of the assay procedures than of any physiological importance.

It is interesting to note that for any one drug, $K_i$ varied significantly from striatum to pons-medulla to ileum (with the exception that the difference between $K_i$ for benactyzine/ileum and $K_i$ for benactyzine/pons-medulla was not statistically significant). Such regional heterogeneity is consistent with observations on QNB (Dawson and Jarrott, unpublished results) and other antagonists acting on brain muscarinic receptors (Kloog et al., 1979). This heterogeneity may well be of physiological importance. One may speculate that postsynaptic receptors may have a similar configuration, but differ from presynaptic receptors. Regional heterogeneity could then reflect differences in the distribution of presynaptic and postsynaptic receptors.

3.2 Interactions of Aprophen with AChE

Aprophen was found to be a mixed competitive-uncompetitive inhibitor of AChE. The competitive and uncompetitive dissociation constants were found to be $0.27 \pm 0.32$ mM and $2.9$ mM (range, $0.9 - 4.6$ mM) respectively. These figures are similar to those for benactyzine, $0.63$ mM and $20.7$ mM respectively (Dawson and Bladen, 1979). Aprophen is a slightly more potent inhibitor than benactyzine, but both are comparatively weak inhibitors.

Aprophen at the relatively high concentration of 1 mM had negligible effects on the rates of ageing of isopropylmethylphosphonyl-AChE and dephosphorylation of diethylphosphoryl-AChE, but inhibited the rate of decarbamylation of dimethylcarbamyl-AChE (Table 2) by 32%. Corresponding effects have been observed for benactyzine (Dawson and Bladen, 1979). The dissociation constant for the benactyzine-dimethylcarbamyl-AChE complex was calculated as $2.9$ mM (Dawson and Bladen, 1979). Benactyzine and aprophen are therefore approximately equi-effective with respect to decarbamylation.

Overall, the effects of aprophen on AChE are of no significance in assessing the therapeutic actions of aprophen in vivo.

4. ACKNOWLEDGEMENTS

Some of the experiments on AChE were performed by Mr M.P. Bladen.

We are grateful to Chemical Defence Establishment, Porton for their gifts of aprophen and T3436.
5. REFERENCES


<table>
<thead>
<tr>
<th>Parameter</th>
<th>Region</th>
<th>Ileum</th>
<th>Pons-medulla</th>
<th>Striatum</th>
<th>Atrium</th>
</tr>
</thead>
<tbody>
<tr>
<td>( K_i ) (nM)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Atropine</td>
<td></td>
<td>2.15 ± 0.15</td>
<td>1.02 ± 0.10</td>
<td>0.56 ± 0.05</td>
<td>2.2</td>
</tr>
<tr>
<td>Aprophen</td>
<td></td>
<td>8.00 ± 1.68</td>
<td>3.75 ± 0.23</td>
<td>2.29 ± 0.32</td>
<td>10.3</td>
</tr>
<tr>
<td>Benactyzine</td>
<td></td>
<td>9.35 ± 0.85</td>
<td>7.10 ± 0.45</td>
<td>3.42 ± 0.61</td>
<td>7.8</td>
</tr>
<tr>
<td>Hyoscine</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>0.9</td>
</tr>
<tr>
<td>T3436 (racemate)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>0.9</td>
</tr>
<tr>
<td>T3436 (R)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>0.3</td>
</tr>
<tr>
<td>( n_H )</td>
<td></td>
<td>0.95 ± 0.05</td>
<td>1.06 ± 0.05</td>
<td>1.03 ± 0.06</td>
<td></td>
</tr>
<tr>
<td>Atropine</td>
<td></td>
<td>1.01 ± 0.04</td>
<td>1.26 ± 0.09</td>
<td>1.08 ± 0.03</td>
<td></td>
</tr>
<tr>
<td>Benactyzine</td>
<td></td>
<td>1.08 ± 0.08</td>
<td>1.05 ± 0.02</td>
<td>0.96 ± 0.06</td>
<td></td>
</tr>
</tbody>
</table>

\( n_H \) is defined in equation 1.

For direct binding studies, concentration of \((^3H)\)-QNB = 44-74 pM.

Results for brain regions and ileum are given as the mean and standard error from four animals.
### TABLE 2

**EFFECT OF APROPHEN ON RATE CONSTANTS FOR REACTIVATION AND AGEING OF INHIBITED ACETYLCHOLINESTERASE**

<table>
<thead>
<tr>
<th></th>
<th>Dephosphorylation</th>
<th>Decarbamylation</th>
<th>Ageing</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>0.0147 ± 0.0010 (3)</td>
<td>0.344 ± 0.014 (4)</td>
<td>0.315 ± 0.009 (2)</td>
</tr>
<tr>
<td>1 mM aprophen</td>
<td>0.0162 ± 0.0008 (2)</td>
<td>0.235 ± 0.013 (5)*</td>
<td>0.288 ± 0.030 (2)</td>
</tr>
</tbody>
</table>

Inhibited AChE = diethylphosphoryl-AChE (for dephosphorylation)  
dimethylcarbamyl-AChE (for decarbamylation)  
isopropylmethylphosphonyl-AChE (for ageing)

*Significantly different from control; P < 0.05*
DISTRIBUTION LIST

MATERIALS RESEARCH LABORATORIES

Chief Superintendent
Superintendent, Organic Chemistry Division
Dr. S.E. Freeman
Dr. R.M. Dawson
Dr. B.M. Paddle
Library
Librarian, Materials Testing Laboratories, N.S.W. Branch
(Through Officer-in-Charge)

DEPARTMENT OF DEFENCE

Chief Defence Scientist
Deputy Chief Defence Scientist
Controller, Projects and Analytical Studies
Controller Service Laboratories and Trials
Army Scientific Adviser
Air Force Scientific Adviser
Navy Scientific Adviser
Chief Superintendent, Aeronautical Research Laboratories
Chief Superintendent, Weapons Systems Research Laboratory,
Defence Research Centre
Chief Superintendent, Electronics Research Laboratory,
Defence Research Centre
Chief Superintendent, Advanced Engineering Laboratory,
Defence Research Centre
Superintendent, Trials Resources Laboratory, Defence Research Centre
Senior Librarian, Defence Research Centre
Librarian, R.A.N. Research Laboratory
Officer-in-Charge, Document Exchange Centre DSTO (16 copies)
Technical Reports Centre, Defence Central Library
Central Office, Directorate of Quality Assurance - Air Force
Deputy Director Scientific and Technical Intelligence, Joint Intelligence Organisation
Head, Engineering Development Establishment
Director General, Army Health Services
Director General, Air Force Health Services
Director General, Naval Health Services
Librarian, Bridges Library, Royal Military College
Command NBCD Officer, RAN NBCD School, HMAS Penguin
Officer-in-Charge, NBC Wing, School of Military Engineering
Director of Medical Services - Army
DEPARTMENT OF PRODUCTIVITY

NASA Canberra Office
Head of Staff, British Defence Research and Supply Staff (Aust.)

OTHER FEDERAL AND STATE DEPARTMENTS AND INSTRUMENTALITIES

The Chief Librarian, Central Library, C.S.I.R.O.
Australian Atomic Energy Commission Research Establishment

MISCELLANEOUS - OVERSEAS

Assistant Director/Armour and Materials, Military Vehicles and Engineering Establishment, Surrey, England
Reports Centre, Directorate of Materials Aviation, Orpington, Kent, England
U.S. Army Standardization Representative, C/o DGAD (NSO), Canberra
The Director, Defence Scientific Information & Documentation Centre, Delhi, India
Colonel B.C. Joshi, Military, Naval and Air Adviser, High Commission of India, Red Hill, A.C.T.
Director, Defence Research Centre, Kuala Lumpur, Malaysia
Exchange Section, British Library, Lending Division, Yorkshire, England
INSPEC: Acquisition Section, Institution of Electrical Engineers Hitchin, Herts, England
Overseas Reports Section, Defence Research Information Centre, Orpington, Kent, England
Engineering Societies Library, New York, U.S.A.
Director, Chemical Defence Establishment, Wilts., England
Director, Chemical Systems Laboratories, Maryland, U.S.A.
Director General, Defence Research Establishment Suffield, Alberta, Canada
Mr. T. Dashiell, U.S. National Leader TTCP Subgroup E, Washington U.S.A.
Dr. A. Bebbington, U.K. National Leader TTCP Subgroup E, Chemical Defence Establishment, Wiltshire, England
Mr. J. Currie, Canada National Leader TTCP Subgroup E, Defence Research Establishment Suffield, Ralston, Alberta, Canada
Dr. L. Leadbeater, U.K. Representative, TTCP E/TP-1, Chemical Defence Establishment, Wiltshire, U.K.
Dr. J.G. Clement, (Canada Representative, TTCP E/TP-1), Defence Research Establishment Suffield, Ralston, Alberta, Canada
Colonel C. Llewellyn, (U.S. Representative, TTCP E/TP-1), Commander, U.S. Army Biomedical Laboratories, Maryland, U.S.A.